Form 4: Unity Biotechnology CLO Acquires 150,000 Stock Options

Alexander Hieu Nguyen, CLO and Head of Operations at Unity Biotechnology, acquired 150,000 stock options on January 22, 2025.

Summary

• Alexander Hieu Nguyen, the Chief Legal Officer and Head of Operations at Unity Biotechnology, acquired 150,000 stock options on January 22, 2025.
• The exercise price of these options is $2.09.
• The options vest over a period of two years, with one-third vesting on December 31, 2025, and the remaining shares vesting in 24 equal monthly installments thereafter, until December 31, 2027.
• The options expire on January 21, 2035.
• Following the transaction, Nguyen directly owns 150,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither inherently positive nor negative.

Positives

• The acquisition of stock options by a key executive like the CLO and Head of Operations can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It provides transparency into the equity-based compensation of key personnel.

Stakeholder Impact

• The granting of stock options aligns the interests of the executive with those of the shareholders, potentially incentivizing them to increase shareholder value.

Key Dates

Keywords

stock options, Unity Biotechnology, insider trading, Form 4, Alexander Hieu Nguyen, UBX, CLO, Head of Operations, equity